Related Experiment Video

Updated: Apr 27, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

25.3K

Successful treatment of mild pediatric kasabach-merritt phenomenon with propranolol monotherapy

Worawut Choeyprasert1, Rungrote Natesirinilkul1, Pimlak Charoenkwan1

  • 1Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.

Case Reports in Hematology
|June 26, 2014
PubMed

Insights

Propranolol effectively treated mild Kasabach-Merritt phenomenon (KMP) in a pediatric case. This vascular tumor treatment showed sustained clinical and hematologic remission after therapy completion.

Area of Science:

  • Pediatric Oncology
  • Vascular Anomalies

Background:

  • Kasabach-Merritt phenomenon (KMP) presents significant mortality risks due to bleeding and treatment resistance.
  • Established KMP treatments include corticosteroids, vincristine, embolization, and surgery, with variable success rates.

Purpose of the Study:

  • To evaluate the efficacy of propranolol monotherapy in a pediatric patient with mild Kasabach-Merritt phenomenon.
  • To assess both clinical and hematologic responses to propranolol treatment for kaposiform hemangioendothelioma.

Main Methods:

  • A five-week-old child diagnosed with mild Kasabach-Merritt phenomenon and kaposiform hemangioendothelioma was treated with propranolol monotherapy.
  • Clinical assessment of the cutaneous lesion and regular hematologic monitoring were performed throughout the treatment and follow-up period.

Main Results:

  • Successful clinical and hematologic remission was achieved with propranolol monotherapy.
  • The patient maintained a stable cutaneous lesion and remained free of hematologic relapse eight months into treatment and six months after discontinuation.

Conclusions:

  • Propranolol monotherapy demonstrates promising efficacy for treating mild pediatric Kasabach-Merritt phenomenon.
  • This approach offers a potentially effective and less invasive treatment option for KMP, warranting further investigation.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.7K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
342
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
528
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
670
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
688